Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or …
AMM Eggermont, M Kicinski, CU Blank… - JAMA …, 2020 - jamanetwork.com
Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the
association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC
1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the
treatment of patients with high-risk stage III melanoma. Design, Setting, and Participants A
total of 1019 adults with stage III melanoma were randomly assigned on a 1: 1 ratio to …
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the
association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC
1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the
treatment of patients with high-risk stage III melanoma. Design, Setting, and Participants A
total of 1019 adults with stage III melanoma were randomly assigned on a 1: 1 ratio to …